tradingkey.logo
tradingkey.logo
Buscar

Nexalin Technology Inc

NXL
Añadir a la lista de seguimiento
0.361USD
-0.019-5.00%
Cierre 07/02, 16:00ETCotizaciones retrasadas 15 min
7.43MCap. mercado
PérdidaP/E TTM

Más Datos de Nexalin Technology Inc Compañía

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Información de Nexalin Technology Inc

Símbolo de cotizaciónNXL
Nombre de la empresaNexalin Technology Inc
Fecha de salida a bolsaSep 16, 2022
Director ejecutivoWhite (Mark)
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 16
Dirección1776 Yorktown
CiudadHOUSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal77056
Teléfono18322600222
Sitio Webhttps://nexalin.com
Símbolo de cotizaciónNXL
Fecha de salida a bolsaSep 16, 2022
Director ejecutivoWhite (Mark)

Ejecutivos de Nexalin Technology Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Nexalin Technology Inc?

Los cinco principales accionistas de Nexalin Technology Inc son: Ms. Marilyn Elson

¿Cuántas instituciones poseen acciones de Nexalin Technology Inc (NXL)?

A fecha de 2026Q1, 43 instituciones poseen acciones de Nexalin Technology Inc, con un valor de mercado combinado de aproximadamente 1.43M, lo que representa el 6.94% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 524945.00.

¿Cuál es la mayor fuente de ganancias de Nexalin Technology Inc?

El 2026Q1, el segmento empresarial Device Sales generó la ganancia más alta para Nexalin Technology Inc, ascendiendo a 136.00K y representando el 45.09% de la ganancia total.